Endpoints News 生物医药· ENDPOINTS·· 2026-10-13AI 评分32
Beam Therapeutics 罕见病基因编辑疗法 I/II 期首批数据提示可纠正突变;Pfizer 将与 Enodia 合作
Beam suggests it can correct mutation; Pfizer to collaborate with Enodia
AI 导读
Beam Therapeutics 公布其罕见病基因编辑疗法 I/II 期试验的初步数据,提示可纠正突变。Pfizer 将与 Enodia 合作。
正文
Beam’s first data on a rare disease gene editing therapy: Beam Therapeutics shared initial data from a Phase 1/2 trial of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news